Business Context and Reporting Period
ImmuCell Corporation (ICCC) filed a Form 8-K on May 8, 2026, reporting a material definitive agreement. The company is incorporated in Delaware and trades on the NASDAQ Capital Market.
Key Financial Metrics
This filing does not report standard periodic financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is a one-time settlement payment.
- Settlement Payment: $2,000,000 to be received from Norbrook Laboratories Limited.
Material Changes
The filing details the resolution of claims arising from a 2019 Development Services and Commercial Supply Agreement with Norbrook Laboratories Limited, which expired on March 31, 2026. Under the new Settlement Deed, Norbrook has agreed to pay ImmuCell $2,000,000. The agreement includes confidentiality undertakings and does not constitute an admission of liability by either party.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the settlement. The settlement is governed by Northern Ireland law.
Investor Verification Checklist
- Verify the timing and method of the $2,000,000 settlement payment receipt.
- Confirm the accounting treatment of the settlement (e.g., recognition as income in the current period).
- Review the confidentiality terms to ensure no undisclosed liabilities remain from the 2019 agreement.
- Check subsequent filings for any updates on the status of the payment or related legal matters.